Up next

Senior Executives Highlight Mergers and Acquisitions and Expansions at DCAT Week ’18

At the DCAT Member Company Announcement Forum, held during DCAT Week, senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) provided the latest major news from their companies impacting the pharmaceutical manufacturing value chain. So what did they report?

The executives highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions. Lonza, DowDuPont, Catalent, Novasep, CordenPharma, Piramal Pharma Solutions, SK biotek, Biocon, Procos, Nosco, AB BioTechnologies, and PolyCrystalLine were among the companies taking the podium to provide their latest developments.

The executives highlighted developments to expand active pharmaceutical ingredient (API) development and manufacturing (both small molecules and biologics), drug-product development and manufacturing (both solid dosage and parenteral drugs), and packaging. A roundup of these developments are provided in the stories below.

Lonza Updates Integration of $5.5-Billion Acquisition of Capsugel

DowDuPont Outlines Integration of Combined Company, Including Excipients Business

Catalent Updates Integration of $950-Million Acquisition of Cook Pharmica

Novasep Announces $65-Million Investment in Biologics

CordenPharma Outlines Integration of Former Pfizer API Facility

Piramal Pharma Solutions CEO Outlines Expansion Plans

SK biotek Outlines Integration of Former BMS API Manufacturing Facility

Biocon COO Highlights Company’s Growth Strategy

Procos CEO Outlines Expansion for High-Potency Manufacturing

Nosco President Discusses Company’s Growth Strategy in Wake of Two Key Acquisitions

AB BioTechnologies CEO Announces $12-Million Expansion

PolyCrystalLine CEO Announces Expansion of Solid-State Chemistry Capabilities

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

What is Top of the Industry’s Sustainability Agenda in 2026?

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry. 

Future-Proofing the Pharma Customer & Supplier Relationship

By
The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

AI: The State of the State in Supply Management 

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.